(Q44980532)

7 December 2017

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study (English)

1 reference

7 December 2017

1 reference

1 reference

Fei-Yuan Hsiao

1

1 reference

7 December 2017

Pei-Hua Hsieh

2

1 reference

7 December 2017

Weng-Foung Huang

3

1 reference

7 December 2017

Yi-Wen Tsai

4

1 reference

7 December 2017

Churn-Shiouh Gau

5

1 reference

7 December 2017

language of work or name

1 reference

1 August 2013

1 reference

7 December 2017

1 reference

7 December 2017

36

1 reference

7 December 2017

8

1 reference

7 December 2017

643-649

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-013-0080-4

7 December 2017

0 references

cites work

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Medically diagnosed infections and risk of childhood leukaemia: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0080-4

Alendronate and risk of esophageal cancer: a nationwide population-based study in Taiwan

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23797604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40264-013-0080-4

1 reference

7 December 2017

1 reference